Top

International Journal of Clinical Oncology

Published in:

01-08-2013 | Original Article

The relationship between glucose metabolism disorders and malignant thyroid disease

Authors: Ayse Ocak Duran, Cüneyd Anil, Alptekin Gursoy, Aslı Nar, Ozden Altundag, Neslihan Bascil Tutuncu

Published in: International Journal of Clinical Oncology | Issue 4/2013

Abstract

Background

Previous studies have shown a positive relationship between insulin resistance and several common adult cancers. The present retrospective study aimed to investigate the association between glucose metabolism disorders (GMDs) and the prevalence of thyroid cancer.

Methods

We investigated the data of 4272 patients who had undergone fine-needle aspiration biopsy (FNAB) of thyroid nodules. The biopsy results were evaluated as diagnostic or non-diagnostic and the diagnostic results were classified as benign, malignant, and indeterminate. In this study, we included 2234 of the above patients who had undergone FNAB at our hospital and whose biopsy results were evaluated as diagnostic and were classified as either benign or malignant. We obtained the cytologic data and the glucose metabolism status of these patients retrospectively.

Results

Of the 2234 patients, 629 (28.1 %) had GMD (impaired fasting glucose, impaired glucose tolerance). Malignant cytology was determined in 106 (4.7 %) patients overall. Of the 629 patients with GMD, 582 (92.5 %) patients had benign cytology and 47 (7.5 %) patients had malignant cytology. Fifty-nine (3.7 %) of the 1605 normoglycemic patients had malignant cytology. Malignant cytology was determined more frequently ın the patients who had GMDs (p < 0.001).

Conclusion

The results demonstrated that thyroid cancer prevalence was higher in patients with GMD. According to our results, GMD should be considered as a risk factor for malignancy in the evaluation of thyroid nodules.

Gursoy A (2010) Rising thyroid cancer incidence in the world might be related to insulin resistance. Med Hypotheses 74:35–36PubMedCrossRef

Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167PubMedCrossRef

Leenhardt L, Grosclaude P, Cherie-Challine L (2004) Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14:1056–1060PubMedCrossRef

Lubina A, Cohen O, Barchana M et al (2006) Time trends of incidence rates of thyroid cancer in Israel: what might explain the sharp increase. Thyroid 16:1033–1040PubMedCrossRef

AACE/AME Task force on Thyroid Nodules (2006) American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 12:63–100

American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:62–69CrossRef

Grote VA, Becker S, Kaaks R (2010) Diabetes mellitus type 2—an independent risk factor for cancer. Exp Clin Endocrinol Diabetes 118:4–8PubMedCrossRef

Friberg E, Orsini N, Mantzoros CS et al (2006) Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 50:1365–1374CrossRef

Huxley R, Ansary-Moghaddam A, Berrington de González A et al (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083PubMedCrossRef

10.

Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef

11.

Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862PubMedCrossRef

12.

Mori M, Saitoh S, Takagi S et al (2000) A review of cohort studies on the association between history of diabetes mellitus and occurrence of cancer. Asian Pac J Cancer Prev 1:269–276PubMed

13.

Pisani P (2008) Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 114:63–70PubMedCrossRef

14.

Jee SH, Ohrr H, Sull JW et al (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194–202PubMedCrossRef

15.

Rapp K, Schroeder J, Klenk J et al (2006) Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49:945–952PubMedCrossRef

16.

Stattin P, Bjor O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30:561–567PubMedCrossRef

17.

Mink PJ, Shahar E, Rosamond WD et al (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156:349–352PubMedCrossRef

18.

Inoue M, Iwasaki M, Otani T et al (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871–1877PubMedCrossRef

19.

Stolzenberg-Solomon RZ, Graubard BI, Chari S et al (2005) Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294:2872–2878PubMedCrossRef

20.

Kabat GC, Kim M, Caan BJ et al (2009) Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 125:c2704–c2710CrossRef

21.

Rezzónico JN, Rezzónico M, Pusiol E et al (2009) Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord 7:375–380PubMedCrossRef

22.

Rezzonico J, Rezzonico M, Pusiol E et al (2008) Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 18:461–464PubMedCrossRef

23.

Vella V, Sciacca L, Pandini G et al (2001) The IGF system in thyroid cancer: new concepts. Mol Pathol 54:121–124PubMedCrossRef

24.

Ciampolillo A, De Tullio C, Perlino E et al (2007) The IGF-I axis in thyroid carcinoma. Curr Pharm Des 13:729–735PubMedCrossRef

25.

Rapoport B, Chazenbalk GD, Jaume JC et al (1998) The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 19:673–716PubMedCrossRef

26.

Boelaert K, Horacek J, Holder RL et al (2006) Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 91:4295–4301PubMedCrossRef

27.

Enewold L, Zhu K, Ron E et al (2009) Rising thyroid cancer incidence in the United States by demographic and tumor characteristics 1980–2005. Cancer Epidemiol Biomarkers Prev 18:784–791PubMedCrossRef

Title: The relationship between glucose metabolism disorders and malignant thyroid disease
Authors: Ayse Ocak Duran
Cüneyd Anil
Alptekin Gursoy
Aslı Nar
Ozden Altundag
Neslihan Bascil Tutuncu
Publication date: 01-08-2013
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-012-0435-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2013

Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer

Recent advances in reconstructive surgery for bone and soft tissue sarcomas

Recent advances in reconstructive surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer